Comparison of the Efficacy of Atorvastatin and Rosuvastatin in Preventing Atrial Fibrillation after Coronary Artery Bypass Grafting: A Double-Blind Randomized Comparative Trial.
Atorvastatin
Atrial fibrillation
Coronary artery bypass
Rosuvastatin calcium
Journal
The journal of Tehran Heart Center
ISSN: 1735-5370
Titre abrégé: J Tehran Heart Cent
Pays: Iran
ID NLM: 101289255
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
27
12
2021
accepted:
03
08
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by disorganized atrial activity and subsequent mechanical atrial failure. Postoperative AF is a frequent complication of coronary artery bypass grafting (CABG). Although there is evidence of decreased AF after CABG with statin usage, information is scarce regarding a direct comparison between atorvastatin and rosuvastatin. The present study was conducted to compare the efficacy of rosuvastatin and atorvastatin in preventing post-CABG AF. The present double-blind randomized comparative clinical trial selected CABG candidates with stable ischemic heart disease or acute coronary syndromes. Atorvastatin (40 mg per day) or rosuvastatin (20 mg per day) was prescribed 1 week before surgery, and the outcomes were compared. Two-hundred patients, 100 cases in each group, completed the study. Twenty-five patients in each group were female, and the mean age was 59.30±8.42 years in the rosuvastatin group and 60.13±9.40 years in the atorvastatin group (P=0.513). The frequency of AF was 31% in the atorvastatin group and 27% in the rosuvastatin group (P=0.534). No significant differences existed between the groups concerning the length of hospital and ICU stay (P=0.333 and P=0.161) and in-hospital and 3-month mortality (P=0.315 and P=0.648). A subgroup analysis of only patients with stable ischemic heart disease could not detect a significant difference between the study groups in any of the investigated outcomes. Our logistic regression analysis showed an association only between age and the incidence of AF after CABG (OR, 1.12; 95% CI, 1.05 to 1.20; P<0.01). Rosuvastatin and atorvastatin are similar concerning the prevention of post-CABG AF, but there is a need for future well-designed multicenter studies on this topic.
Sections du résumé
Background
UNASSIGNED
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by disorganized atrial activity and subsequent mechanical atrial failure. Postoperative AF is a frequent complication of coronary artery bypass grafting (CABG). Although there is evidence of decreased AF after CABG with statin usage, information is scarce regarding a direct comparison between atorvastatin and rosuvastatin. The present study was conducted to compare the efficacy of rosuvastatin and atorvastatin in preventing post-CABG AF.
Methods
UNASSIGNED
The present double-blind randomized comparative clinical trial selected CABG candidates with stable ischemic heart disease or acute coronary syndromes. Atorvastatin (40 mg per day) or rosuvastatin (20 mg per day) was prescribed 1 week before surgery, and the outcomes were compared.
Results
UNASSIGNED
Two-hundred patients, 100 cases in each group, completed the study. Twenty-five patients in each group were female, and the mean age was 59.30±8.42 years in the rosuvastatin group and 60.13±9.40 years in the atorvastatin group (P=0.513). The frequency of AF was 31% in the atorvastatin group and 27% in the rosuvastatin group (P=0.534). No significant differences existed between the groups concerning the length of hospital and ICU stay (P=0.333 and P=0.161) and in-hospital and 3-month mortality (P=0.315 and P=0.648). A subgroup analysis of only patients with stable ischemic heart disease could not detect a significant difference between the study groups in any of the investigated outcomes. Our logistic regression analysis showed an association only between age and the incidence of AF after CABG (OR, 1.12; 95% CI, 1.05 to 1.20; P<0.01).
Conclusion
UNASSIGNED
Rosuvastatin and atorvastatin are similar concerning the prevention of post-CABG AF, but there is a need for future well-designed multicenter studies on this topic.
Identifiants
pubmed: 37637286
doi: 10.18502/jthc.v18i2.13321
pii: JTHC-18-115
pmc: PMC10459339
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115-121Informations de copyright
Copyright © 2023 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences.
Références
Int J Cardiol. 2012 Jan 12;154(1):78-81
pubmed: 22019059
Ann Surg. 1997 Oct;226(4):501-11; discussion 511-3
pubmed: 9351718
Clin Cardiol. 2016 Sep;39(9):491-6
pubmed: 27505443
Circulation. 1996 Aug 1;94(3):390-7
pubmed: 8759081
Avicenna J Med. 2012 Jul;2(3):65-70
pubmed: 23826549
Heart Rhythm. 2019 Apr;16(4):502-510
pubmed: 30366160
QJM. 2008 Nov;101(11):845-61
pubmed: 18725372
Hellenic J Cardiol. 2019 Jan - Feb;60(1):40-47
pubmed: 29307691
Am J Cardiol. 2015 Jun 1;115(11):1523-8
pubmed: 25843920
J Am Coll Cardiol. 2011 Dec 6;58(24):e123-210
pubmed: 22070836
Int J Cardiol. 2013 Sep 10;167(6):3058-60
pubmed: 23194786
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
BMC Cardiovasc Disord. 2014 Aug 13;14:99
pubmed: 25117689
Ann Noninvasive Electrocardiol. 2013 Jan;18(1):58-68
pubmed: 23347027
Br J Pharmacol. 2008 Jan;153(1):21-33
pubmed: 17952108
J Thorac Dis. 2018 Mar;10(3):1960-1967
pubmed: 29707352
Circulation. 2020 Oct 6;142(14):1320-1329
pubmed: 33017213
J Cardiovasc Dev Dis. 2021 Feb 26;8(3):
pubmed: 33652637
Res Cardiovasc Med. 2012 Nov;1(1):23-7
pubmed: 25478484
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1286-92
pubmed: 15187217
J Am Coll Cardiol. 2006 Aug 15;48(4):854-906
pubmed: 16904574
Heart Surg Forum. 2013 Jun;16(3):E158-61
pubmed: 23803242
Rev Esp Cardiol. 2010 Sep;63(9):1054-60
pubmed: 20804701
Heart. 2006 Aug;92(8):1177-82
pubmed: 16844883
Circ J. 2015;79(3):495-502
pubmed: 25746525